8-K: DataMeds AI Reports Q2 2026 Results, Faces Net Loss

DataMeds AI announced its second quarter 2026 financial results, reporting a 14% sequential revenue increase to $1.779 million but a significant rise in net operating loss to $18.363 million.

Summary

• DataMeds AI reported its financial results for the second quarter ended June 30, 2026.
• Revenues grew 14% sequentially to $1.779 million, exceeding management projections.
• The company experienced a net operating loss of $18.363 million for the quarter, a significant increase from $6.672 million in the same period last year.
• This increase in loss is attributed to expenses related to debt extinguishment and general administrative costs.
• The company completed a 1-for-50 reverse stock split in May 2026.
• A new funding round of $6.5 million was secured in June 2026.
• The corporate name changed from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, with a stock symbol change to MEDS on NASDAQ Capital Markets.
• The Health Lives Here app, in partnership with NFL Alumni Health, is expected to launch in September 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses and a substantial increase in operating expenses, despite revenue growth and strategic initiatives.

Positives

• Sequential revenue growth of 14% to $1.779 million in Q2 2026, surpassing management expectations.
• Secured $6.5 million in new funding in June 2026 to support corporate turnaround.
• Restructured $14.5 million in pre-existing debt, creating a path to preferred equity swap.
• Entered into a joint venture with KareRx, adding Electronic Benefits Verification (EBV) services and access to 200,000 patient lives.
• The Health Lives Here app launch with NFL Alumni Health is slated for September 2026.
• The company rebranded to DataMeds AI, Inc. and changed its stock symbol to MEDS on NASDAQ Capital Markets.

Negatives

• Net operating loss increased significantly to $18.363 million in Q2 2026, compared to $6.672 million in Q2 2025.
• Net loss per share was $7.13 for Q2 2026, compared to $5.40 for Q2 2025.
• Total liabilities increased to $52.26 million as of June 30, 2026, from $42.91 million as of December 31, 2025.
• Accumulated deficit widened to $137.14 million as of June 30, 2026, from $111.03 million as of December 31, 2025.
• The Neuritek Therapeutics, Inc. acquisition was terminated in May 2026.

Risks

• The company faces significant operating losses and a widening accumulated deficit.
• The company's ability to maintain compliance with NASDAQ listing standards was a concern addressed by the reverse stock split.
• Forward-looking statements indicate potential future challenges and uncertainties regarding business strategy, product development, and market acceptance.
• The pending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings, and HealthBridge Associates involves complex integrations and regulatory approvals.

Future Outlook

The company anticipates launching the Health Lives Here consumer app with NFL Alumni Health in September 2026, targeting GLP-1 users. They also plan to launch the medical food Forzet and close the Datavault Transaction. Future plans include acquiring a CLIA lab for direct-to-consumer testing and potentially launching a drone service for medical product delivery.

Management Comments

• "Having been in leadership now for just under three months, I am excited with the significant progress we are making towards the important milestone of launching the Health Lives Here app together with NFLAH."
• "As we move towards this important milestone, we have successfully begun consolidating the key healthcare infrastructure needed to deliver a workflow for the patient that will result in a seamless patient experience that will allow patients to engage with their healthcare in a way that was previously not possible."
• "We intend to engage the patient through telemedicine, a consumer app and their local independent pharmacist who will be educated on the pharmaceutical-adjunct products we provide through our relationship with Tollo Health that are intended to help mitigate drugs side effects and improve their effectiveness at the initial HLH app launch."
• "Ultimately we intend to move all of this data onto the blockchain, protected through our Datavault AI (NASDAQ: DVLT) license that provides us with patent protection on healthcare data tokenization and monetization, allowing us to provide patients with an opportunity to participate in the revenue generated through the sale of their health data."

Industry Context

StockSavvy.ai notes that DataMeds AI is operating in the rapidly evolving Health IT sector, focusing on AI, blockchain, and consumer-facing health applications. The planned launch of the Health Lives Here app with NFL Alumni Health targets a specific patient demographic (GLP-1 users) and delivery channel (independent pharmacies), reflecting a trend towards personalized and accessible healthcare solutions. The company's strategy of integrating various technologies and data monetization aligns with broader industry movements towards value-based care and data-driven insights.

Related Party Transactions

• Due from related party of $26,068 as of June 30, 2026.
• Accounts payable, related party of $25,500 as of June 30, 2026.
• Due to related parties of $225,000 as of December 31, 2025 (none as of June 30, 2026).

Stakeholder Impact

• Shareholders: The reverse stock split and significant net loss may impact share price and investor confidence. However, the new funding and strategic initiatives like the HLH app launch could offer future upside.
• Creditors: The restructuring of $14.5 million in pre-existing debt and the new funding may improve the company's ability to meet its obligations.
• Patients: The Health Lives Here app and companion medical food Forzet aim to improve healthcare experiences, particularly for those in rural communities and on GLP-1 medications.
• Partners (e.g., NFL Alumni Health, KareRx): The success of joint ventures and partnerships is crucial for the execution of the company's strategy.

Next Steps

• Launch of the Health Lives Here consumer app in September 2026.
• Launch of the medical food Forzet.
• Closing of the Datavault Transaction.
• Acquire a CLIA lab to offer direct-to-consumer testing.
• Perfect intended launch of a drone service to deliver medical products.

Key Dates

Recommendation

The company shows promising strategic initiatives and revenue growth, but the substantial increase in net operating loss and widening accumulated deficit present significant financial risks. The successful execution of the Health Lives Here app launch and the Datavault transaction are critical catalysts. Given the mixed signals of growth potential versus financial distress, a 'hold' recommendation is prudent pending further clarity on profitability and operational execution.

Keywords

DataMeds AI, Health IT, Artificial Intelligence, Blockchain, Healthcare App, Pharmacy, GLP-1, Telemedicine